Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Indexado |
|
||||
DOI | 10.3389/FPHYS.2018.01800 | ||||
Año | 2018 | ||||
Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Sepsis syndrome is the most important cause of mortality in critically ill patients admitted to intensive care units (ICUs). However, current therapies for its prevention and treatment are still unsatisfactory, and the mortality rate is still high. Non-septic ICU patients are vulnerable to acquire sepsis syndrome. Thus, a preventive treatment for this population is needed. During sepsis syndrome and endotoxemia, severe hypotension, tachycardia, oxidative and immune response increase, multiple organ dysfunction syndrome (MODS) and decreased survival are observed. Leptin administration protects against negative effects of sepsis syndrome and endotoxemia. Furthermore, it is has been reported that leptin elevates blood pressure mediated by sympathetic nervous system activation. However, whether leptin administration before sepsis induction mediates its protective effects during sepsis through blood pressure regulation is not known. Therefore, we investigated whether pre-treatment of leptin improves blood pressure and MODS, resulting in survival increase during endotoxemia. The results showed that leptin administration before endotoxemia induction reduced both the hypotension and tachycardia characteristically observed during endotoxemia. Notably, this protective effect was observed early and late in the course of endotoxemia. Endotoxemia-induced MODS decreased in leptin-treated rats, which was reflected in normal values for liver and kidney function, inhibition of muscle mass wasting and maintenance of glycemia. Furthermore, leptin pre-treatment decreased the oxidative stress burst in blood and blunted the increased pro-inflammatory cytokines TNF-alpha, IL-1 beta, and IL-6 observed during endotoxemia. Remarkably, according to the leptin-induced increase in survival, leptin pre-administration decreased the risk for death associated with sepsis syndrome at early and late times after endotoxemia induction. These results show a potential preventive therapy against sepsis syndrome and endotoxemia in vulnerable patients, based in the beneficial actions of leptin.
Ord. | Autor | Género | Institución - País |
---|---|---|---|
1 | Vallejos, Alejandro | Hombre |
Universidad Nacional Andrés Bello - Chile
Instituto Milenio de Oceanografía - Chile Millennium Institute on Immunology and Immunotherapy - Chile |
2 | Olivares, Pedro | Hombre |
Universidad Nacional Andrés Bello - Chile
|
3 | VARELA-LEKANDA, DIEGO ERNST | Hombre |
Universidad de Chile - Chile
|
4 | ECHEVERRIA-LEAL, CRISTIAN MAURICIO | Hombre |
Universidad de Atacama - Chile
Universidad Bernardo O'Higgins - Chile |
5 | Cabello-Verrugio, Claudio | Hombre |
Universidad Nacional Andrés Bello - Chile
Instituto Milenio de Oceanografía - Chile Millennium Institute on Immunology and Immunotherapy - Chile |
6 | PEREZ-LEIGHTON, CLAUDIO ESTEBAN | Hombre |
Pontificia Universidad Católica de Chile - Chile
|
7 | SIMON-PINO, FELIPE ALONSO | Hombre |
Universidad Nacional Andrés Bello - Chile
Instituto Milenio de Oceanografía - Chile Millennium Institute on Immunology and Immunotherapy - Chile |
Fuente |
---|
Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) |
Fondo Nacional de Desarrollo Científico y Tecnológico |
Ministerio de Economía, Fomento y Turismo, Chile |
Universidad Andrés Bello |
Millennium Institute on Immunology and Immunotherapy |
Iniciativa Cientifica Milenio of the ministry of Economy, development and Tourism (Chile) |
Agradecimiento |
---|
This work was supported by research grants from Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT; 1161288, 1160900, 11170840, and 1161646), Millennium Institute on Immunology and Immunotherapy (P09-016-F), Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD) is a Millennium Nucleus supported by the Iniciativa Cientifica Milenio of the Ministry of Economy, Development and Tourism (Chile) (UNAB DI-741-15/N). |
Funding. This work was supported by research grants from Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT; 1161288, 1160900, 11170840, and 1161646), Millennium Institute on Immunology and Immunotherapy (P09-016-F), Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD) is a Millennium Nucleus supported by the Iniciativa Científica Milenio of the Ministry of Economy, Development and Tourism (Chile) (UNAB DI-741-15/N). |